NOVOLIN 70/30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLIN 70/30 (NOVOLIN 70/30).
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
| Metabolism | Primarily metabolized by insulin-degrading enzyme (IDE) in the liver, kidneys, and peripheral tissues. |
| Excretion | Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible. |
| Half-life | Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours. |
| Protein binding | <5% bound to serum proteins (primarily albumin). |
| Volume of Distribution | Approximately 0.3-0.6 L/kg; reflects distribution into extracellular fluid and tissues. |
| Bioavailability | Subcutaneous: 100% (complete absorption). |
| Onset of Action | Subcutaneous: Within 30-60 minutes. |
| Duration of Action | Subcutaneous: Up to 24 hours. Note: Peak effect occurs at 4-12 hours; intermediate-acting profile with a pronounced peak. |
| Molecular Weight | 5808 Da (for insulin, as a protein; Novolin 70/30 is a mixture of regular and NPH insulin, but the molecular weight of insulin is consistent) |
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >60 mL/min: No adjustment. GFR 30-60 mL/min: Monitor glucose, may need dose reduction due to prolonged insulin action. GFR <30 mL/min: Reduce dose by 25-50% and monitor closely. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% due to impaired gluconeogenesis. Child-Pugh Class C: Avoid use or reduce dose significantly (e.g., by 50-75%) with close monitoring. |
| Pediatric use | Children: 0.5-1 unit/kg/day subcutaneously, typically administered as 2-3 injections before meals; individualize based on age and blood glucose. For adolescents: similar to adult dosing. |
| Geriatric use | Start with lower doses (e.g., 0.2-0.3 unit/kg/day) due to increased risk of hypoglycemia; titrate slowly; monitor renal function and cognitive status. |
| 1st trimester | Insulin does not cross the placenta in significant amounts. Intensive glycemic control is recommended to reduce risk of congenital malformations. No known teratogenicity. |
| 2nd trimester | Insulin requirements may increase due to placental hormones. Continued use is safe and indicated. Monitor glucose closely. |
| 3rd trimester | Insulin requirements may increase further. Safe for use; tight control minimizes fetal macrosomia and neonatal hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for NOVOLIN 70/30 (NOVOLIN 70/30).
| Placental transfer | Insulin does not cross the placental barrier in significant amounts due to its molecular size and structure, except when bound to insulin antibodies. |
| Breastfeeding | Insulin is excreted in breast milk in minimal amounts (<1% of therapeutic dose) and is not expected to cause adverse effects in the infant. However, caution in mothers with hypoglycemia unawareness. Monitor infant for signs of hypoglycemia. |
■ FDA Black Box Warning
Changes in insulin strength, manufacturer, type, or method of administration should be done under close medical supervision to prevent hypoglycemia or hyperglycemia.
| Serious Effects |
Hypoglycemia (current episode)Known hypersensitivity to insulin or any excipients
| Precautions | Hypoglycemia is the most common adverse effect, Hypersensitivity and allergic reactions, Hypokalemia, Fluid retention and heart failure with concomitant thiazolidinedione use, Dosage adjustment required in renal or hepatic impairment |
| Food/Dietary | Meal timing and composition significantly affect glycemic response. Administer insulin 30 minutes before a meal that contains carbohydrates to avoid postprandial hyperglycemia or hypoglycemia. Rapid absorption of simple sugars may require dose adjustments. Alcohol can increase hypoglycemic risk; limit intake and do not drink on an empty stomach. No specific food-drug interactions known. |
Loading safety data…
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | Insulin does not cross the placenta in significant amounts. No known teratogenic risk. Poor glycemic control increases risk of congenital anomalies, macrosomia, and neonatal hypoglycemia. |
| Fetal Monitoring | Monitor blood glucose, HbA1c, fetal growth (ultrasound), and fetal well-being (non-stress test, biophysical profile) in third trimester. |
| Fertility Effects | No direct effects on fertility. Uncontrolled diabetes may impair fertility and increase risk of miscarriage. |
| Clinical Pearls | NOVOLIN 70/30 is a biphasic insulin containing 70% NPH (intermediate-acting) and 30% regular (short-acting) insulin. It should be administered subcutaneously 30 minutes before meals to align peak insulin action with postprandial glucose rise. Due to its fixed ratio, it is less flexible than basal-bolus regimens and may not be optimal for patients with variable meal schedules or erratic glucose patterns. Avoid use in insulin pumps. Shake or roll vial/pen gently to resuspend before each use. |
| Patient Advice | Shake or roll the vial or pen gently until it looks uniformly cloudy before each injection. · Inject your dose subcutaneously into abdomen, thigh, or upper arm, rotating sites within the same region. · Take your insulin 30 minutes before a meal; it has both peak and long-acting components. · Do not skip meals after injection to prevent hypoglycemia. · Always keep a fast-acting glucose source (e.g., glucose tablets, juice) available for low blood sugar. · Do not share insulin pens or needles with others. · Store unused insulin in the refrigerator; keep the one in use at room temperature for up to 28 days. · Monitor your blood glucose regularly and report any unusual patterns or severe hypo/hyperglycemia to your provider. |